{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-105245","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2024-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.769568+00:00","generated_at":"2026-05-29T08:38:01.149584+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Relmada Phase 3 Reliance II trial for REL-1017 in MDD deemed futile at interim analysis","bullets":["DMC interim analysis indicates Reliance II is futile, unlikely to meet primary efficacy endpoint with statistical significance.","No new safety signals reported; DMC did not identify any safety concerns.","Relmada to evaluate next steps for REL-1017 program; continues development of REL-P11 for metabolic disease.","Cash and cash equivalents ~$54.1M as of Sep 30, 2024, providing runway.","Sergio Traversa, CEO, expressed disappointment and gratitude to participants."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-105245","json":"https://secwatch.observer/filing/0001213900-24-105245.json","markdown":"https://secwatch.observer/filing/0001213900-24-105245.md","text":"https://secwatch.observer/filing/0001213900-24-105245.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024105245/0001213900-24-105245-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024105245/ea0223563-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T08:38:01.149584+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}